Alliance Pharma PLC (LON:APH) chairman David Cook provided a reasonably upbeat assessment of prospects and said “we continue to see some strong performances from our key brands”.
In a short release issued ahead of the international healthcare group’s annual meeting, he told investors the integration of the Biogix business and the Amberen brand into the US-based operations was “progressing very well”, with the process largely complete.
“Current trading and expectations for Amberen remain in line with our pre-acquisition forecasts,” he added.
"We remain confident in our ability to weather any ongoing disruption to our business in those areas of the world which continue to be challenged by the global pandemic, and to deliver full-year results in line with market expectations.”
Further commentary on the company’s first-half performance and the full-year outlook will be provided in a July trading statement.
Alliance focuses on the acquisition and licensing of pharmaceutical and healthcare products. Over the past 20 years, the group has made more than 35 acquisitions, which include healthcare and pharma businesses and rights to products.